For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

While there is plenty of excitement about the new gene editing treatment, Casgevy, some in the sickle-cell community say they have been let down before and worry about being let down again.

CRSP and partner VRTX’s one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia (TDT ...

In December, Vertex entered into an agreement with the Centers for Medicare & Medicaid Services to help increase patient access to its gene therapy, Casgevy, which treats a rare blood disorder ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in ...

In December, Vertex entered into an agreement with the Centers for Medicare & Medicaid Services to help increase patient access to its gene therapy, Casgevy, which treats a rare blood disorder ...

CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle ... for brand-new medicines and others seeking label expansions. Third, Amgen is an excellent ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...